SIRT6 promotes intrahepatic cholangiocarcinoma development by reprogramming glutamine metabolism via enhanced GLUL
Our findings establish SIRT6 as an oncogenic driver in ICC by orchestrating glutamine metabolic reprogramming and highlight the SIRT6-GLUL axis as a potential therapeutic target for ICC.
Authors
- Junyan Tao (ORCID: https://orcid.org/0000-0002-5249-970X)
- Hua Wu (ORCID: https://orcid.org/0000-0001-8209-3447)
- Ruitao Long
- Zhongyu Cheng
- Chanyuan Chen
- Timothy E. Long (ORCID: https://orcid.org/0000-0001-9515-5491)
- Haifeng Zhang (ORCID: https://orcid.org/0000-0002-9670-2642)
- Lei Li (ORCID: https://orcid.org/0000-0002-6771-7917)
- Nanjin Ding
- Mi Zhang (ORCID: https://orcid.org/0000-0003-4549-6540)
- Chuanrui Xu (ORCID: https://orcid.org/0000-0003-3225-4083)
- Tingjie Wang (ORCID: https://orcid.org/0000-0001-9238-0968)
- Dong Kuang (ORCID: https://orcid.org/0000-0001-9568-0333)
- Zhilu Ma
Institutions
- University of Pittsburgh (US)
- Zhengzhou University (CN)
- Henan Cancer Hospital (CN)
- Huazhong University of Science and Technology Hospital (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Gut
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1136/gutjnl-2025-335729
- Citations
- 3
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 2.81